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Background: In resource-limited settings, most young infants with signs of 
severe infection do not receive the recommended inpatient treatment with 
intravenous broad spectrum antibiotics for 10 days or more because such 
treatment is not accessible, acceptable or affordable to families. this trial 
was initiated in the Democratic Republic of Congo, Kenya and nigeria to 
assess the safety and efficacy of simplified treatment regimens for the young 
infants with signs of severe infection who cannot receive hospital care.
Methods: this is a randomized, open-label equivalence trial in which 3600 
young infants with signs of clinical severe infection will be enrolled. the pri-
mary outcome is treatment failure in 7 days after enrollment, which includes 
death or worsening of the clinical condition on any day, or no improvement 
in the clinical condition by day 4 of treatment. Secondary outcomes include 
compliance with study therapy, adverse effects due to the study drugs and 
relapse or death during the week after completion of treatment. 
Discussion: the results of this study, along with ongoing studies in pakistan 
and Bangladesh, will inform the development of global policy for treatment 
of severe neonatal infections in resource-limited settings. 
Key Words: neonates, young infants, antibiotic treatment, sepsis, 
severe infection
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Neonatal infections are responsible for 700,000–800,000 neo-natal deaths that occur globally every year.1 Over 95% of all 
neonatal and infant deaths due to infections occur in developing 
countries, where rates of home delivery are high and unhygienic con-
ditions during and after birth are common. Appropriate treatment of 
neonatal infections could prevent the majority of infection-specific 
deaths, making it one of most important child survival interventions.2
Currently, it is recommended that young infants (from birth up 
to 2 months of age) with signs of severe infection be referred for inpa-
tient care and treated with intravenous broad spectrum antibiotics such 
as a combination of ampicillin and gentamicin for 7-10 days.3 the 
efficacy of the recommended treatment in reducing the risk of death 
of young infants with severe infections is well accepted. However, 
most such infants in developing countries do not currently receive 
inpatient care,4–7 largely because treatment is not readily accessible 
or because hospitalization is not acceptable or feasible for families.
A technical advisory group organized by Save the Children/
Saving newborn lives, united States Agency for International 
Development and World Health Organization (WHO) in london 
in 2007 recommended large, well-designed studies to evaluate 
simplified antibiotic regimens for treatment of neonatal sepsis out-
side hospital settings.8 Such regimens could include an optimal 
combination of oral and intramuscular antibiotics or injectable to 
oral “switch” regimens that would be feasible in weak health sys-
tems. As a result, 2 randomized trials, using a common protocol, 
were initiated in pakistan and Bangladesh. A similar trial in Africa 
was required to support the development of global policy.
In 2009, WHO sent out a call for African sites interested in 
conducting a randomized, open-label equivalence trial similar to 
the ones initiated in Asia. Five sites in Africa were selected after an 
external review process, one site each in Democratic Republic of 
Congo (DRC) and Kenya and 3 sites in nigeria (Ibadan, Ile-Ife and 
Zaria) to take part in this trial using a common protocol. this article 
describes the design of the Africa trial.
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OBJECTIVES
the goal of the study is to inform global policy on the use 
of simplified antibiotic treatment regimens for young infants with 
signs of clinical severe infection who cannot receive hospital care.
•  primary objective: to evaluate simpler antibiotic regimens for 
provision of safe and effective treatment of 0- to 59-day-old 
young infants with signs of clinical severe infection whose fami-
lies do not accept or cannot access referral-level care, compared 
with a combination of injectable penicillin and gentamicin injec-
tions for 7 days.
•  Secondary objectives: to assess family acceptance of different 
treatment options and compliance with them, and to document 
health worker requirements in terms of time and costs for each 
treatment regimen.
METHODS
Study Design
this is an individually randomized, open-label, multicenter 
equivalence trial. the 5 sites in DRC, Kenya and nigeria are fol-
lowing the same protocol, quality control and coordination mecha-
nisms to contribute to an overall sample size.
Study Settings
Democratic Republic of Congo
the infant mortality and neonatal mortality rates in DRC are 
97 per 1000 and 31 per 1000 live births, respectively.9 the study is 
being conducted in rural areas of 4 health zones in north and South 
ubangi districts, in the province of equateur, DRC. the population of 
the study area is about 300,000. In the first year of the study, a total of 
about 12,000 births were identified in the study population. the opera-
tional primary healthcare functions in the study area are embedded 
within Health Zones; each Health Zone consists of between 100,000 to 
250,000 inhabitants and has 1 general referral hospital. Health Zones 
are typically divided into 8–24 Health Areas, each with 1 Health Cen-
tre that covers a population of 5000 to 10,000 inhabitants; 30 Health 
areas are included in the study. Health centers are the primary site of 
care, where skilled health providers and the community intersect, and 
curative and health promotion activities are conducted. each health 
center is staffed by 1 trained nurse, who oversees the activities of com-
munity health workers (CHWs) (literate village volunteer workers), 
who primarily engage in preventive and promotional activities.
Kenya
the infant mortality and neonatal mortality rates in Kenya 
are 52 per 1000 and 31 per 1000 live births, respectively.10 the 
study is being conducted in the counties of Busia, Bungoma and 
Kakamega (in the districts of Busia, Butula, Bungoma West, Bun-
goma South, Bungoma east, teso South, teso north and mumias) 
in Western Kenya. the population of the study area is about 
350,000. In the first year of the study, a total of about 13,000 births 
were identified in the study population. thirty-four clusters were 
selected for the study; each cluster has 1 dispensary or health facil-
ity manned by 2 health workers. these health units do not normally 
have inpatient services for all cadres of patients and are the level-2 
health facilities as per the ministry of Health classification.
Nigeria
the infant mortality and neonatal mortality rates in nige-
ria are 75 per 1000 and 47 per 1000 live births, respectively.11 In 
nigeria, the study used a cadre of health workers called commu-
nity health extension workers (CHeWs). CHeWs receive 2 years of 
training in government-supported training institutes in basic issues 
on maternal and child health, child nutrition, treatment of infections, 
immunization and environmental health, oral and mental health. 
they are also trained and allowed to provide injectable therapy.
Ile-Ife. the study is being conducted in the Ife Central and 
east local Government Areas (Ile-Ife community), a semi-urban 
community in Osun State, in Southwestern nigeria. the estimated 
population of study area is about 350,000. In the first year of the 
study, about 11,000 births were identified. the rate of refusal of 
hospital admission is very high, about 50%, usually for religious 
and cultural reasons. Deliveries by skilled birth attendants are very 
low, although booking at health facilities for antenatal care is high.
Ibadan. the study is being conducted in Ido and lagelu peri-
urban local Government Areas of Oyo State in the south western part 
of nigeria. the population is mainly rural with some suburban areas, 
and the study population under surveillance is about 200,000. In the 
first year of the study, about 8000 births were identified. Financial 
constraints are a barrier to referral to health services. most women 
attend antenatal clinics while pregnant either in government hospitals 
or mission homes usually owned by traditional birth attendants; less 
than 50% deliver in these government health facilities.
Zaria. the third study site in nigeria is Zaria local Gov-
ernment Area, located in the northern part of Kaduna State in the 
north West geopolitical zone of nigeria. It is made up of more 
than 100 urban, peri-urban and rural settlements populated by 
predominantly Hausa/Fulani muslims. the study population of 
approximately 150,000 is located in 8 wards in the old, traditional 
part of Zaria town. In the first year of the study, about 6000 births 
were identified. Although more than half the women attend antena-
tal clinics during pregnancy, less than 10% deliver in health facili-
ties or under the supervision of trained attendants. Although home 
delivery is the norm, less than half of these home births are super-
vised by a traditional birth attendant.
Study Participants
A summary of site description and implementation strategy 
is given in table 1 and the overall study approach in Figure 1.
Identification of Pregnancies and Births, Surveillance 
for Illness
A pregnancy surveillance system has been established in all 5 
study sites, with the aim of identifying newborns as soon as possible 
after birth. CHWs in DRC and Kenya, and CHeWs in nigeria, visit 
all identified births on days 1, 3, 7, 14, 21, 28, 35, 42, 49 and 60 after 
birth. At each home visit, they assess the newborn for signs of illness 
and counsel the families on recognition of these signs (stopped feed-
ing well according to the mother, reported convulsions, fast breath-
ing, severe chest indrawing, temperature of ≥38.0°C or <35.5°C, 
movement only on stimulation, yellow soles or pus from umbilicus, 
eye or skin). Young infants with any of these signs are advised to go 
to a health center or hospital. those who refuse referral or are unable 
to go to a facility are assessed by a study health worker.
Screening and Enrollment
Screening and enrollment are conducted by enrollment 
nurses. In DRC and Kenya, this takes place at the health center or 
dispensary. In nigerian sites, it takes place at the child’s home. Young 
infants, 0–59 days of age, are eligible for inclusion in this study if:
•  they have signs of clinical severe infection: not feeding well 
on observation, movement only when stimulated, severe chest 
indrawing and axillary temperature ≥38.0°C or <35.5°C;
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•  they have no exclusion criteria: very low weight (<1500 g at 
the time of presentation), hospitalization for illness in the last 
2 weeks or previous inclusion in the study, any sign of critical 
illness (unconscious, convulsions, unable to feed at all, apnea, 
unable to cry, cyanosis, dehydration, bulging fontanel, major 
congenital malformations inhibiting oral antibiotic intake, active 
bleeding requiring transfusion, surgical conditions needing hos-
pital referral and persistent vomiting [defined as vomiting after 3 
attempts to feed the baby within 30 minutes]);
• their parents do not accept hospital referral; and
• their parents give consent to participate in the study.
Randomization
the enrolled infants are classified into 2 age groups, 0–6 
days and 7–59 days, and randomly assigned to 1 of the treatment 
regimens. the unit of randomization is the individual infant with 
randomization stratified by age group and study site. An age-strati-
fied randomization scheme with block size of 8 was computer-gen-
erated off-site at WHO using StAtA version 10.0 (StAtA Corp 
lp, College Station, tX) by a person not involved with the study. 
For allocation concealment, treatment codes are printed on small 
pieces of cardboard pieces which are then folded once and sealed in 
sequentially numbered opaque envelopes (2 color-coded envelopes, 
one each for 0–6 days and 7–59 days age groups).
In the Kenyan and nigerian sites, randomization is done cen-
trally by a designated person who keeps the randomization enve-
lopes. the enrollment nurse calls this person at the time of enroll-
ment of a new infant, who opens the next envelope according to 
the age category and conveys the treatment allocation. this process 
takes place by phone and is confirmed by short message service. In 
DRC where mobile phone communication is not reliable, each facil-
ity where enrollment occurs is given a block of 8 envelopes for each 
age group, and used blocks are regularly replaced so that a sufficient 
number of envelopes are always available at the facility.
Intervention and Comparison Groups
•  treatment regimen A (reference treatment): injectable gen-
tamicin once daily and injectable procaine penicillin once daily 
for 7 days (14 injections in total);
•  treatment regimen B: injectable gentamicin once daily and oral 
amoxicillin twice daily for 7 days (7 injections in total);
•  treatment regimen C: injectable gentamicin once daily and 
injectable procaine penicillin once daily for 2 days, thereafter 
oral amoxicillin for 5 days (4 injections in total);
•  treatment regimen D: injectable gentamicin once daily and oral 
amoxicillin twice daily for 2 days, thereafter oral amoxicillin 
twice daily for 5 days (2 injections in total).
All treatments are given at a health facility or at home. the 
injections are given once daily by a health worker at a facility or at 
home, whereas oral medicines are given by the mother under the 
supervision of CHWs at home. Daily assessments are conducted by 
health workers to identify any worsening of the child’s condition. 
Home visits to assess the outcome of the treatment are conducted 
by independent outcome assessment nurses at days 4, 8, 11 and15 
after enrollment to detect treatment failure or relapse.
the rationale for selection, dosages and durations of antibiot-
ics is given in detail elsewhere in this supplement.12 the combination 
of penicillin and gentamicin is used globally for treating presumed 
sepsis in the both neonatal period group and the second month of 
life.3,13–16 the combination of penicillin/amoxicillin and gentamicin 
targets common neonatal pathogens such as Escherichia coli, other 
enteric gram-negative rods and streptococci. the antibiotic dosages 
for young infants enrolled in the study are injection procaine penicil-
lin in a dose of 50,000 units/kg once daily Im, injection gentamicin 
in the range 4.0–7.5 mg/kg/day once daily Im (depending on age 
of the young infant) and oral amoxicillin in suspension in a dose of 
100 mg/kg/day (less than 2 kg are given 75 mg/kg/day), divided in 2 
equal doses. All treatment regimens are being used for 7 days.
Provision of Treatment
In DRC and Kenya, all injectable treatment is provided at a 
health facility by the treatment nurse, who also provides the first daily 
dose of oral therapy. mothers observe the first dose being given and 
are instructed to provide the second daily dose of oral amoxicillin at 
home in the same manner. In nigeria, the first treatment (injectable 
or oral) after randomization is provided by the treatment nurse at the 
child’s home. treatment on subsequent days is provided by CHeWs.
Study Outcomes
An independent outcome assessment nurse visits enrolled 
infants on days 4, 8, 11 and 15 after the day of the enrollment to 
TABLE 1. Summary of Site Description and Implementation Strategy
Democratic  
Republic of Congo Kenya
Nigeria-1
Ibadan
Nigeria-2
Ile-Ife
Nigeria-3
Zaria
Population 300,000 350,000 200,000 350,000 150,000
Identification of pregnancies  
and births
CHW/TBA CHW/TBA TBA/CHEWs TBA/CHEWs TBA/CHEWs
Home visits for newborn care CHW CHW CHEW CHEW CHEW
Screening and study enrollment Enrollment nurse Enrollment nurse or 
clinical officer
Screening by CHEW
Enrollment by  
enrollment nurse
Screening by CHEW
Enrollment by  
enrollment nurse
Screening by CHEW
Enrollment by  
enrollment nurse
Treatment 
provision (and 
daily assess-
ment to detect 
worsening)
Injection and  
1 oral dose
Auxiliary nurse Health centre nurse CHEW CHEW CHEW
Second oral  
dose
Observed by CHW Observed by CHW Observed by CHEW Observed by CHEW Observed by CHEW
Outcome assessment blinded to  
treatment allocation (on days 
4, 8, 11 and 15 of enroll-
ment and for confirmation of 
worsening)
Outcome  
assessment  
nurse
Outcome  
assessment nurse
Outcome  
assessment nurse
Outcome  
assessment nurse
Outcome  
assessment nurse
Supervision Community  
coordinator
Community  
coordinator
Study  
supervisor
Study  
supervisor
Study  
supervisor
TBA indicates traditional birth attendant.
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assess outcome. All outcome assessments are conducted at the 
young infant’s home.
Primary Outcome
the primary outcome is treatment failure before or at 
the day 8 visit. treatment failure is defined by any one of the 
following:
• Death.
•  Clinical deterioration (hospitalization, emergence of any sign 
of critical illness at any time or a new sign of clinical severe 
infection after the day 2 visit or reemergence of a sign of clinical 
severe infection on day 4 after initial disappearance).
•  no improvement in clinical condition by day 4 (if there was a 
single sign of clinical severe infection at enrollment, persistence 
of the sign; if there were multiple signs at enrollment, persistence 
of >1 sign).
•  not cured by day 8 (persistence of any sign of clinical severe 
infection on day 8 of enrollment).
•  Development of a serious adverse event (SAe) other than death 
that is thought to be related to the study antibiotics, for example, 
Informed consent to 
participate in study by 
the family
Community-based surveillance for neonatal illness
Follow up of pregnancies, identification of births by CHWs/TBAs
Home visits by CHWs to identify "danger signs"* on Day 1, 3, 7, 14, 21, 28, 35, 42, 49, 60
Management of illness by a nurse or clinical officer
Sick young infant taken to health facility by CHW (or visited by Health Worker at home)
Examined for signs of possible serious infection by Health Worker
Hospital referral recommended and assisted if these signs present
If family accepts 
referral, follow up*
Screening
If the family does not 
accept referral, the 
young infant is 
classified as:
Critically ill
(see definition in 
text)
Clinical severe infection
(Feeding poorly, moves only on 
stimulation, severe chest 
indrawing, temperature <35.5oC 
or >38oC)
No signs of 
clinical severe 
infection
Enrollment and randomization
by age groups
<7 days and 7-59 days
(colour coded envelopes)
Treatment at health facility (or at home)
• Treatment for 7 days according to randomization code
• Injections given once daily by Health Worker at facility or at home
• Oral medicines given by mother under supervision of HW/CHW
• Daily assessment by Health Worker providing treatment to detect worsening
Independent Outcome assessment
• Outcome assessment by independent assessor (experienced nurse or physician)
• Scheduled outcome assessment at Day 4, 8, 11 and 15 after enrolment
• Additionally, confirmation of worsening when detected by treating health worker
Excluded from 
study
Excluded from 
study
*Only if families provide consent for this follow-up visit to document outcome
FIGURE 1. Overall study approach.
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organ failure, anaphylactic reaction, severe diarrhea, dissemi-
nated and severe rash.
Secondary Outcomes
• Death between days 9–15 after enrollment.
•  Relapse (after disappearance of all signs of clinical severe infec-
tion by day 8, emergence of any sign of critical illness or clinical 
severe infection between days 9–15 after enrollment).
• Adherence to the allocated treatment between days 1–8.
Sample Size
In the absence of population-based incidence data, the 
incidence of possible severe bacterial infection among neonates 
and young infants was conservatively assumed to be about 5% in 
Africa. this estimate was based on earlier studies conducted in 
Bangladesh and India where about 10–15% of all newborns had an 
illness with at least 1 sign of possible severe bacterial illness during 
follow-up,7,17,18 and 2 studies with more specific diagnostic criteria 
reported a lower incidence of possible severe bacterial infection 
of 7–10%.17,18
the sample size calculations were performed based on 
comparing the failure rates observed with treatment regimen A 
(reference treatment regimen: injection penicillin and gentamicin 
for 7 days) with the failure rates expected with the 3 experimental 
treatment regimens. For each comparison, the point estimate of the 
failure rate difference (experimental–reference treatment) between 
the 2 treatment regimens and its 2-sided 95% confidence interval 
will be calculated. the alternative treatment will be judged to be 
“of similar effectiveness” to the reference treatment A (assumed 
treatment failure rate 10%) if the upper bound of the 95% confi-
dence interval of the difference lies below the allowed “similarity 
margin” of +5%. the required sample size for 90% power to dem-
onstrate the similarity of 2 treatments assuming that the true failure 
rates with the reference treatment and the experimental treatment 
regimens will be identical (assumed to be 10%) works out to be 
760 “analyzable” infants per arm who would be included in the 
prespecified per-protocol analysis. Assuming that approximately 
15% of randomized infants will be excluded from the per-protocol 
analysis for failure to adhere treatment, the required sample size is 
900 infants for each treatment regimen (a total of approximately 
3600 infants).
Data Collection
Data collection is done by CHWs/CHeWs during home vis-
its and includes data on all births as well as deaths within the first 
2 months of life. the CHWs/CHeWs also screen young infants for 
illness. Data are collected on the paper-based standard case report 
forms that have been extensively field tested and revised after pilot 
testing. enrollment nurses complete a screening form after exami-
nation for every sick young infant who was referred or brought 
to them by CHW/CHeW. they complete a baseline information 
form at enrollment for every enrolled infant. Daily treatment and 
assessment records are maintained by the treating health worker. 
the outcome assessment nurses complete an assessment form at 
days 4, 8, 11 and 15 days after randomization and when an infant is 
sent to them for assessment by the treating health worker because 
of suspected worsening of clinical condition. names or other iden-
tifiers of the infant and his/her family are not included on the study 
forms. All completed forms are checked by study supervisors for 
completeness before they are entered into the computer.
Data Management
Individual sites are responsible for their own day-to-day data 
management activities. each individual site has its own data man-
agement team, including a data manager and team of data entry 
clerks. At each site, the data entry clerks enter data from paper 
forms into the data management system, which stores the data in a 
data base. the data management system consists of a front-end and 
a back-end. the front-end, prepared in C++, is the user interface 
that the data manager and the data entry clerks use to interact with 
the database, whereas the back-end in Structured Query language 
stores the database itself. All data are double-entered and discrep-
ancies verified to remove data entry errors. the data manager then 
proceeds to run range and consistency checks built into the data 
management system. After resolving all range and consistency 
errors in consultation with the data collection staff, the data man-
ager checks for inconsistencies in information across different case 
report forms using inbuilt checks and resolves them in consulta-
tion with the field coordinators and if necessary with the principal 
investigators of the study.
the cleaned data are sent every month to the central data 
coordination center at london School of Hygiene and tropical 
medicine in london. Additional data quality checks are carried 
out, and feedback is provided to the study sites on a monthly basis.
Analysis Plan
the primary analysis will be a combined analysis across 
all the sites. Simple comparisons of means and proportions by 
treatment group will be used to check whether the randomization 
scheme has in fact resulted in baseline comparability of treatment 
groups. the primary analyses will be for equivalence between the 
reference treatment and the 3 experimental arms; it will consist of 
the comparison of proportions of infants with treatment failure in 
each treatment arm.
Analysis will be conducted on a per-protocol basis and on 
an intention-to-treat basis. Although the former is more conserva-
tive to establish equivalence of treatment regimens and will be the 
primary analysis for this study, the latter will take into account the 
possibility of differences in adherence to treatment across treat-
ment arms despite the best efforts of the research team. In order for 
an enrolled infant to be included in the per-protocol analysis, he/
she should have received: (1) all antibiotic doses due to be received 
for the first 3 days of treatment or by the time of treatment failure, 
and (2) at least 50% of all scheduled doses of each antibiotic on 
days 4 to 7 or by the time of treatment failure. Furthermore, for 
inclusion in the per-protocol analysis, treatment outcome should 
have been assessed among days 2–4, days 5–8 and vital status on 
day 8 known.
each experimental regimen will be compared with the ref-
erence regimen and the difference in the risk of treatment failure 
together with 95% confidence intervals will be calculated. Analyses 
will be performed with data from all sites combining the 2 age sub-
groups, adjusted for any baseline covariates which were unbalanced 
at baseline and with the addition of dummy variables for site and 
age group.
Subgroup analysis of primary and secondary outcomes will 
be performed by age subgroups (0–6 days and 7–59 days at the 
time of enrollment). univariate and multivariate regression analy-
ses will be undertaken to identify clinical predictors of treatment 
failure and death despite antibiotic treatment.
Ethical Issues
Study Approvals
the trial protocol and all associated data collection instru-
ments and consent forms were approved by the local Institutional 
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Review Boards, the WHO ethical Review Committee and the Insti-
tutional Review Board of the london School of Hygiene and tropi-
cal medicine. the trial was registered as ACtRn12610000286044 
with Australian new Zealand Clinical trials Registry. the trial fol-
lows Council for International Organizations of medical Sciences 
and Good Clinical practice guidelines.
Informed Consent
Communities in all sites were introduced to the study before 
initiation of enrollment. this was achieved through meetings with 
community leaders and with community groups. Informed written 
consent is obtained for the home visits for pregnancy and birth, 
enrollment, treatment as well as for follow-up visits of nonenrolled 
infants. Health workers were trained to facilitate referral through 
counseling using integrated management of childhood illness guid-
ance for assisting referral. Only babies whose families refuse refer-
ral and are willing to document this by witnessed signature/thumb-
print are enrolled.
Monitoring of Potential Adverse Events
the families are asked to contact the CHW/CHeW if any 
adverse events occur. In the case of a SAe, CHWs contact their 
supervising CHW and CHeWs contacts their outcome assessment 
nurse. the assessment nurse documents the adverse event and con-
veys this to the Community Coordinator/Supervisor. SAes such as 
death, hospitalization, unable to pass urine for 12 hours, anaphylac-
tic reaction, severe dehydration due to diarrhea, injection abscess or 
disseminated or severe rash are reported to WHO within 48 hours 
of their occurrence. this information is also provided on a regu-
lar basis to the Data Safety monitoring Board (DSmB) and ethics 
committees.
Rescue Therapy
At any time during the study follow-up, young infants 
identified as treatment failures according to the study protocol are 
referred to a hospital. If the parents refuse to take the infant to the 
hospital, the infant is offered rescue therapy (intramuscular ceftri-
axone for 7 days).
Data Safety Monitoring Board
the DSmB is responsible for monitoring and assessing the 
safety of the trial and consists of an epidemiologist, a statistician 
and 1 clinician scientist/researcher from each of the 3 countries. 
the DSmB convenes at least once a year in a face-to-face meeting, 
which consists of both an open and a closed session. two interim 
analyses will be conducted: when one third of participants and 
when two thirds of participants have been enrolled and treated.
the DSmB determined that the trial will be stopped or mod-
ified if an interim analysis shows that the proportion of neonatal 
deaths between treatment and control groups differ by at least 2 
standard errors with a P value of 0.01. Furthermore, termination or 
modification may be recommended for any other perceived safety 
concern based on clinical judgment, including but not limited to 
a higher than anticipated rate for any component of the primary 
endpoint or unexpected SAes. For this purpose, the SAe forms are 
sent to the DSmB on a quarterly basis.
Quality Assurance
Training of Health Workers
training of health workers for the study was a 2-step pro-
cess. training sessions for “master trainers” from all sites were 
held using the WHO/unICeF Home Care for newborns course, 
the WHO/unICeF Young Infant integrated management of child-
hood illness course (for study nurses) and a study-specific proce-
dures course. these site-specific master trainers were experienced 
physicians and nurses; they subsequently trained all CHWs/
CHeWs and nurses employed by the study. All supervisors and site 
coordinators were also trained in all courses.
Standardization
extensive standardization exercises were conducted for each 
cadre of study health workers. For CHW/CHeW standardization 
sessions, we identified 5–10 eligible young infants in a community 
or a nearby health facility and asked each CHW/CHeW to assess 
these infants while being observed by a trained facilitator. Assess-
ments included weighing the child, assessing danger signs (abil-
ity to feed, convulsions, elevated respiratory rate, chest indrawing, 
high or low temperature, lethargy and yellow soles). the facilita-
tor compared his/her findings with those of each health worker to 
identify errors. After the exercise, the trainees were given feedback; 
those needing further standardization were given targeted refresher 
training.
the same standardization process was used for all staff, 
including enrollment nurses, treatment nurses, outcome assessment 
nurses, health center nurses, supervisors and coordinators. these 
healthcare workers were all trained to identify signs of critical ill-
ness. Standardization exercises were conducted at the start of the 
study and subsequently every 3–6 months for all health workers 
to ensure that all of them assessed clinical signs in a similar way.
Supervision
Supervised, accompanied visits and independent, unaccom-
panied visits are carried out regularly by the supervisors. principal 
investigators and coinvestigators also make random visits to study 
sites to check quality.
Site Monitoring
monthly progress reports are prepared by all sites, sent to 
the WHO coordinating center for the study and reviewed critically 
on a monthly basis. Regular conference calls are held to discuss the 
progress of the trial. Data-based monitoring, as well as verification 
of SAe forms, is carried out by the data coordination center in col-
laboration with the WHO study coordination team.
WHO technical staff conducts at least 2 monitoring visits to 
each site every year. A detailed structured review of study imple-
mentation is conducted at each visit. the key areas that are moni-
tored included the recruitment rate, clinical practices such as iden-
tification of danger signs and critical signs, detection of treatment 
failure as well as data management and overall study procedures. 
All study documentation is checked. A proportion of completed 
case report forms, all treatment failures and all adverse events are 
reviewed. Recommendations arising from the site visit are dis-
cussed with the principal Investigators at the sites and followed up 
for action. monitoring visits are also conducted by external moni-
tors who are not associated with the study.
Project Coordination
the project is being coordinated by the WHO Department 
of maternal, newborn, Child and Adolescent Health. technical 
advice is provided by a technical Advisory Group, which includes 
all principal investigators, the WHO coordination team and exter-
nal experts, and convenes at least once a year in a face-to-face 
meeting. london School of Hygiene and tropical medicine assists 
in quality control through database monitoring, prepares necessary 
reports for the DSmB, trial Advisory Group and liaises with WHO 
study coordination team.
Timeline
the enrollment of study participants began in April 2011 at 
all study sites and is likely to be completed by may 2013.
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DISCUSSION
evaluation of simpler treatment regimens for severe neona-
tal infection has been identified as an important global research 
priority to prevent neonatal mortality.20 the current WHO recom-
mendation for treatment of severe neonatal infection in neonates 
and young infants is hospitalization and treatment with injectable 
penicillin (benzyl penicillin or ampicillin) plus gentamicin for at 
least 10 days, requiring 50 injections.3 In practice, these guidelines 
are rarely implemented in many low resource settings, due to inad-
equate referral systems or parental refusal of referral.
the simplest safe and effective antibiotic regimen for 
treating possible severe bacterial infection in young infants is 
unknown. Although 7 days of treatment with once daily procaine 
penicillin and gentamicin injections appears to be safe and effec-
tive, this still involves 14 injections, which may also be difficult 
in some settings.7 If a simpler treatment option—that is, one that 
is shorter in duration and requires fewer injections—was shown 
to be safe and effective, it would make treatment more accessi-
ble, acceptable and less expensive for families. Furthermore, such 
simpler treatments could be provided at first-level health facili-
ties, at outpatient facilities and possibly even at home by trained 
health workers and would contribute substantially to increasing 
coverage of antibiotic therapy.
the ongoing trial described in this article is a multicenter 
study involving 5 sites in 3 countries in Africa. It is the largest 
community-based study evaluating simplified antibiotic regimens 
for clinical severe infection in neonates and young infants. the 
study is an individually randomized trial, which is the most rigor-
ous design for comparing treatment regimens. Blinding of therapy 
was not possible because of the differences in delivery of the regi-
mens. Although there is an element of subjectivity involved in the 
assessment of treatment failure based on the presence or absence of 
clinical signs, an independent outcome assessor who is blinded to 
the treatment regimen assesses the study outcome.
this study in 3 African countries, combined with 2 similar 
ongoing studies in Bangladesh and pakistan, will provide evidence 
on the simplified antibiotic regimen for treatment of sepsis in out-
patient settings where referral is not possible. this evidence will 
be generalizable to Africa and South Asia and will allow devel-
opment of global policy to manage severe bacterial infections in 
young infants.
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